Tocilizumab in Giant Cell Arteritis

@article{Mariano2018TocilizumabIG,
  title={Tocilizumab in Giant Cell Arteritis},
  author={Vincent J Mariano and W. Frishman},
  journal={Cardiology in Review},
  year={2018},
  volume={26},
  pages={321–330}
}
Giant cell arteritis is a granulomatous immune-mediated vasculitis of medium and large vessels. It most commonly affects white females over the age of 50 and is the most common primary vasculitis in the United States. Treatment of this disease has classically been with high-dose corticosteroids, but this therapy has been associated with severe morbidity and mortality. Tocilizumab, a humanized monoclonal antibody targeting the interleukin-6 receptor, has been used with great efficacy and safety… Expand
Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19

References

SHOWING 1-10 OF 67 REFERENCES
Efficacy of tocilizumab in refractory giant cell arteritis.
Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.
Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis
Tocilizumab in glucocorticoid-naïve large-vessel vasculitis.
Tocilizumab for giant cell arteritis: an amazing result
...
1
2
3
4
5
...